The following is an excerpt.
California’s $3 billion stem-cell agency plans to make a few changes in response to an assessment last month by the Institute of Medicine, an outside panel of scientific experts.
The Institute of Medicine (IOM) report praised the California Institute for Regenerative Medicine (CIRM) for supporting innovative science, but also cited problems with conflicts of interest and governance structure. In particular, it raised concerns that 13 members of its 29-member board come from research institutions that receive CIRM funds. Under the proposed changes, these board members would abstain from votes to approve grants, although they would still be able to participate in discussions about them.
Read the full article here: California stem-cell institute reacts to critical report
